Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China
Cancers · 03.04.2026 · 18 (7) · 1160
DOI: 10.3390/cancers18071160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 03.04.2026. Verfasst von Shan Gao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Beijing Jishuitan Hospital, Capital Medical University, Xicheng District, Beijing 100035, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation.
Abstract (Originalsprache)
Background
Although multiple pomalidomide-based combinations are active in relapsed and/or refractory multiple myeloma (RRMM), comparative data to guide regimen selection remain limited.
Methods
A total of 230 patients with RRMM from 12 centers in China who received pomalidomide-based regimens were included in this retrospective analysis. Overall response rate (ORR) and progression-free survival (PFS) were compared across regimens incorporating bortezomib or ixazomib (V/IPD), carfilzomib (KPD), or daratumumab (DPD), and multivariable analyses were performed to identify prognostic factors.
Results
The overall ORR was 73.9%, with rates of 63%, 79%, and 85% in the V/IPD (n = 66), KPD (n = 69), and DPD (n = 95) cohorts, respectively. ORR differed significantly between V/IPD and DPD (p = 0.0165), driven by a higher proportion of ≥VGPR in the DPD group. The median PFS for the entire cohort was 17.4 months (95% CI: 13.7–20.1), compared with 15.4 months (95% CI: 12.8–20.5), 14.2 months (95% CI: 6.9–not estimable), and 19.2 months (95% CI: 15.1–24.9) for V/IPD, KPD, and DPD, respectively, without significant differences. In multivariable analysis, DPD was associated with improved ORR (HR 4.83, p < 0.001) but not with PFS. R-ISS stage III predicted inferior response (HR 0.35, p = 0.04), whereas ≥3 prior lines of therapy correlated with shorter PFS (HR 1.77, p = 0.012). Adverse events were predominantly hematologic, with limited grade 3–4 toxicity and no treatment-related mortality.
Conclusions
This multicenter real-world analysis clarifies the relative positioning of commonly used pomalidomide-based regimens in RRMM and underscores the importance of treatment timing and disease stage in optimizing outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology Department, Beijing Jishuitan Hospital, Capital Medical University, Xicheng District, Beijing 100035, China.
- Hematology Department, Peking Union Medical College Hospital, Beijing 100023, China.
- Hematology Department, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
- Hematology Department, Hengshui People's Hospital, Hengshui 053000, China.
- Hematology Department, The Affiliated Hospital of Qingdao University, Qingdao 266005, China.
- Hematology Department, Fuzhou University Affiliated Provincial Hospital, Fuzhou 350001, China.
ORCID-Profile: Li Bao
Förderung
- Beijing Natural Science Foundation
Zitieren
APA
Gao, S., Zhuang, J., Liu, A., Wang, D., Wang, W., Li, X., Wang, Z., Fang, M., Gong, M., Jia, Z., Wu, S., Xu, Z., Wang, G., & Bao, L. (2026). Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China. Cancers, 18(7), 1160. https://doi.org/10.3390/cancers18071160
Vancouver
Gao S, Zhuang J, Liu A, Wang D, Wang W, Li X, et al. Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China. Cancers. 2026;18(7):1160. doi:10.3390/cancers18071160
BibTeX
@article{Gao2026,
author = {Gao, Shan and Zhuang, Junling and Liu, Aijun and Wang, Dongmei and Wang, Wei and Li, Xin and Wang, Zhihong and Fang, Meiyun and Gong, Ming and Jia, Zhilin and Wu, Sun and Xu, Zheng and Wang, Genjie and Bao, Li},
title = {Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China},
journal = {Cancers},
year = {2026},
volume = {18},
number = {7},
pages = {1160},
doi = {10.3390/cancers18071160}
}
EUVIMED